GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » Earnings per Share (Diluted)

Kaleido Biosciences (Kaleido Biosciences) Earnings per Share (Diluted) : $-2.16 (TTM As of Dec. 2021)


View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences Earnings per Share (Diluted)?

Kaleido Biosciences's Earnings per Share (Diluted) for the three months ended in Dec. 2021 was $-0.48. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $-2.16.

Kaleido Biosciences's EPS (Basic) for the three months ended in Dec. 2021 was $-0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2021 was $-2.16.

Kaleido Biosciences's EPS without NRI for the three months ended in Dec. 2021 was $-0.48. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2021 was $-2.16.


Kaleido Biosciences Earnings per Share (Diluted) Historical Data

The historical data trend for Kaleido Biosciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaleido Biosciences Earnings per Share (Diluted) Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Earnings per Share (Diluted)
Get a 7-Day Free Trial -1.23 -2.10 -3.36 -2.44 -2.16

Kaleido Biosciences Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.58 -0.56 -0.54 -0.48

Competitive Comparison of Kaleido Biosciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Kaleido Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaleido Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's PE Ratio falls into.



Kaleido Biosciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Kaleido Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (A: Dec. 2021 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-90.288-0)/41.860
=-2.16

Kaleido Biosciences's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (Q: Dec. 2021 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-20.272-0)/42.600
=-0.48

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Kaleido Biosciences  (OTCPK:KLDO) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Kaleido Biosciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Kaleido Biosciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaleido Biosciences (Kaleido Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.
Executives
Alison S Long officer: Chief Medical Officer KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan officer: Chief Scientific Officer C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella director, officer: Chief Executive Officer 79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas director 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener director C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke officer: CHIEF FINANCIAL OFFICER C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo officer: Principal Accounting Officer 25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn officer: General Counsel 128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney director, officer: Executive Chair 65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Kaleido Biosciences (Kaleido Biosciences) Headlines

From GuruFocus

Kaleido Biosciences Reports Third Quarter 2021 Financial Results

By Marketwired Marketwired 11-01-2021

Kaleido Biosciences Announces Pricing of Public Offering of Common Stock

By GlobeNewswire GlobeNewswire 02-04-2021

Kaleido Biosciences Reports First Quarter 2021 Financial Results

By Marketwired Marketwired 05-04-2021